1 University Avenue Macquarie University NSW 2109 AUSTRALIA www.cochlear.com



ASX Announcement

18 July 2023

Cochlear Limited announces Andrew Denver's intention to retire from the Cochlear Board

Cochlear Limited today announced that Non-executive Director Andrew Denver has advised his intention to retire from the Cochlear Board at the end of the next annual general meeting which will be held on 17 October 2023.

Mr Andrew Denver joined the Cochlear Board on 1 February 2007 and has served as a member of the Audit and Risk, Medical Science, Nomination and Product & Services Innovation Committees.

Cochlear Chair, Alison Deans said, "Andy has provided invaluable counsel in his 16 years of service to the Cochlear Board, including as former Chair of the Product & Services Innovation Committee. Andy's extensive experience in the medical device and healthcare industries, along with his significant management experience globally in these industries, have contributed greatly to Cochlear's strategic direction. Andy's deep knowledge in commercialisation and risk management of medical technologies has greatly assisted the delivery of long-term value to shareholders. His tenure has enabled time for an orderly renewal and transition of critical Board skills."

Cochlear's Board and management team sincerely thank Andy for his significant contribution to Cochlear and wish him well for the future.

For further information, please contact:

Analysts Media

Kristina Devon Kirsten Impey

Vice President Investor Relations Director Corporate Communications, Awareness & Brand

Email: kdevon@cochlear.com Email: kimpey@cochlear.com

Ph: + 61 2 9611 6691 Ph: +61 2 9611 6210

This announcement is authorised by the Board of Directors.